Intellia therapeutics, inc. (NTLA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-109,399

-99,533

-90,323

-89,391

-85,927

-85,343

-90,240

-82,894

-76,268

-67,543

-54,143

-46,269

-37,576

-31,634

-26,316

-21,853

-17,993

-12,397

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

5,841

5,600

5,267

5,036

4,788

4,500

4,076

3,714

3,352

3,000

2,566

2,041

1,577

1,104

831

662

482

328

0

0

0

Equity-based compensation

14,656

15,091

15,657

17,034

17,531

17,046

20,060

18,851

16,799

15,322

10,741

9,549

8,533

6,715

5,163

3,687

2,005

1,308

0

0

0

Accretion of investment discounts

2,503

3,725

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Benefit from intraperiod tax allocation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

9,777

-2,927

786

-4,421

-3,875

-2,924

-1,680

5,845

5,023

4,017

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

2,061

1,763

3,646

1,228

1,045

-310

472

1,374

1,392

1,893

1,325

892

340

979

327

695

392

525

0

0

0

Operating right-of-use assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-166

-153

-468

-583

-788

-1,022

-1,088

-909

-952

-902

3,282

3,179

3,344

6,435

0

0

0

-

-

-

-

Accounts payable

154

1,880

2,207

1,538

1,529

232

-321

-1,417

525

-488

1,398

1,481

917

1,784

84

-1,229

-112

335

0

0

0

Accrued expenses

5,092

2,310

2,400

3,422

1,784

2,780

3,515

2,951

2,678

2,394

1,611

1,745

1,291

3,050

1,326

1,354

1,232

805

0

0

0

Deferred revenue

-23,431

-27,122

-11,120

-8,699

-6,304

-3,936

-13,294

-13,287

-13,184

-12,988

-12,583

-11,752

64,475

67,975

66,568

70,635

2,464

9,312

0

0

0

Operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-155

-149

-142

-247

-125

-105

-129

29

-30

-37

71

108

150

0

0

0

Net cash used in operating activities

-120,332

-103,240

-83,116

-70,122

-64,940

-61,257

-74,025

-78,465

-71,648

-65,276

-58,380

-49,096

34,132

36,109

45,028

49,371

-16,006

-1,763

0

0

0

Purchases of property and equipment

6,106

6,794

5,814

6,082

6,041

6,358

7,163

7,407

7,779

10,091

11,099

9,444

9,319

6,165

3,609

3,606

3,046

2,554

0

0

0

Purchases of marketable securities

308,965

297,030

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

392,000

329,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

76,929

25,176

-258,724

-229,088

-253,237

-260,782

-7,163

-7,407

-7,779

-10,091

-11,099

-9,444

-9,319

-6,165

-3,609

-3,606

-3,046

-2,554

0

0

0

Proceeds from sale of Class A-1 and A-2 preferred units and Series B preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

74,661

0

0

0

Payments to acquire in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

600

800

900

1,000

1,100

0

0

0

Payment of preferred unit and preferred stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

100

149

2,755

2,755

2,671

0

0

0

Proceeds from common stock offerings, net of offering costs

73,145

72,256

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from options exercised

3,062

3,086

3,411

5,399

4,292

10,652

10,105

8,296

7,829

1,156

0

0

0

-

-

-

-

-

-

-

-

Payment of common stock offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

2,764

0

0

0

-

-

-

-

Net cash provided by financing activities

77,299

76,434

87,032

42,812

37,496

40,217

152,172

150,363

149,654

142,981

1,125

-1,100

168,546

167,304

166,587

235,157

64,765

70,288

0

0

0

Net increase (decrease) in cash and cash equivalents

33,896

-1,630

-254,808

-256,398

-280,681

-281,822

70,984

64,491

70,227

67,614

-68,354

-59,640

193,359

197,248

208,006

280,922

45,713

65,971

0

0

0

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Purchases of property and equipment unpaid at period end

1,104

800

1,165

521

814

1,071

1,126

1,182

1,130

805

2,747

3,917

2,550

3,090

1,019

247

830

219

0

0

0

Right-of-use assets acquired under operating leases

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from at-the-market offerings unpaid at period end

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of in-process research and development unpaid at period end

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-300

-400

600

0

0

0

Financing costs incurred but unpaid at period end

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-